Herzinsuffizienz: Die Neue Leitlinien

Carsten Tschöpe Kardiologie, Campus Virchow Klinikum

Berlin

1

Stadiengerechte Basistherapie 2012 NYHA I

NYHA II

NYHA III

NYHA IV

ACE – Hemmer (AT1 Blocker) Beta-Blocker

Aldosteronantagonismus Ivabradin Digitalis Diuretika Defi/CRT 4

Weiterhin bestehende hohe Mortalität bei der Herzinsuffizienz

Reduction in relative risk of mortality vs placebo

ACEI*

β-blocker*

MRA*

ARB*

16%

17%

(4.5% ARR; mean follow up of 41.4 months) SOLVD-T1,2

(3.0% ARR; median follow-up of 33.7 months)

30% 34% (5.5% ARR; mean follow up of 1.3 years) CIBIS-II3

(11.0% ARR; mean follow up of 24 months) RALES4

CHARMAlternative5

Iva

19% Shift

 However, significant mortality remains: ~50% of patients die within 5 years of diagnosis 6–8

1. McMurray et al. Eur Heart J 2012;33:1787–847; 2. SOLVD Investigators. N Engl J Med 1991;325:293–302; 3. CIBIS-II Investigators. Lancet 1999;353:9–13; 4. Pitt et al. N Engl J Med 1999;341:709-17;–50; 5. Granger et al. Lancet 2003;362:772–6; 6. Go et al. Circulation 2014;129:e28-e292; 7. Yancy et al. Circulation 2013;128:e240–327; 8. Levy et al. N Engl J Med 2002;347:1397–402

5

Ponikowski P, et al. Eur J Heart Fail 2016 & EHJ 2016 (online available) 6

Recommendations for cardiac imaging in patients with suspected or established heart failure

HFrEF HFmrEF HfpEF

7

Definition of heart failure with preserved (HFpEF), midrange (HFmrEF) & reduced ejection fraction (HFrEF)

8

Recommendations for treatment of patients with HF with preserved ejection fraction and heart failurewith mid-range ejection fraction

9

Recommendations for diagnostic tests in patients with heart failure

Eisenkapazität

10

II a - Indikation Eisendefizienz CONFIRM-HF Effekt von iv Eisengaben

Ponikowski et al EHF 201511

Gregory Lewis, presented at AHA Scientific Sessions 2016 14

Gregory Lewis, presented at AHA Scientific Sessions 2016 15

Recommendations to prevent or delay the development of overt heart failure or prevent death before the onset of symptoms

1. Metformin 2. Metformin plus Empagliflozin Ziel Hba1c bei DM und HF > 7%

16

SGLT-2 Hemmer - Renale Glucose Re-Absorption wird blockiert Fast die gesamte gefilterte Glucose wird im proximalen Tubulus durch die sodium glucose co-transporter SGLT-2 und SGLT-1 re-absorbiert, In gesunden Individuen filtern die Glomeruli wobei SGLT-2 für ca. 90% in dem S1+S2 Segment, ca. 180 g Glucose pro Tag und SGLT-1 für ca. 10% in dem S3 Segment zuständig ist

Glucose

SGLT-2

~90% SGLT-1

~10%

Lee YJ, Han HJ. Kidney Int Suppl 2007

17

Cardiovascular Death

3.7% vs 5.9% 38% relative risk reduction

EMPA-REG, NEJM 2015

18

Hospitalization for Heart Failure

2.7% vs 4.1% 35% relative risk reduction

EMPA-REG, NEJM 2015

19

20

Medikamentöse Therapie bei HFrEF

21

Medikamentöse Therapie bei HFrEF

22

Nicht-linearer Zusammenhang zwischen Ruheherzfrequenz und Auftreten von Herzinsuffizienz Metaanalyse: Ruheherzfrequenz als Risikofaktor für Auftreten von Herzinsuffizienz; n = 7.073 (1.181 x Inzidenz Herzinsuffizienz)

Kahn et al., J Am Heart Assoc. 2015;4:e001364

Therapeutic algorithm for a patient with symptomatic HF with reduced ejection fraction. (cont..)

The Do`s and Don`ts of CRT

NO

Yes

Ruschitzka HFA 2016 mod. Cleland EHJ 2013

Therapeutic algorithm for a patient with symptomatic HF with reduced ejection fraction. (cont..)

Therapeutic algorithm for a patient with symptomatic HF with reduced ejection fraction. 2016 ESC Guideline - Sacubitril/valsartan

• ESC-HF guidelines provide strong Class I recommendation for sacubitril/valsartan • Endorsement showing in section 7.3.2 of 2016 Guidelines, discussed in light of PARADIGM-HF Pharmacological treatments indicated in patients with symptomatic (NYHA Class II-IV) HFrEF Recommendations

Class

Level

An ACEi is recommended, in addition to a beta blocker, for symptomatic patients with HFrEF to reduce the risk of HF hospitalization and death

I

A

A beta blocker is recommended, in addition an ACEi, for patients with stable, symptomatic HFrEF to reduce the risk of HF hospitalization and death

I

A

An MRA is recommended for patients with HFrEF, who remain symptomatic despite treatment with an ACEi and a beta-blocker, to reduce the risk of HF hospitalization and death

I

A

Sacubitril/valsartan is recommended as a replacement for an ACEi to further reduce the risk of HF hospitalization and death in ambulatory patients with HFrEF who remain symptomatic despite optimal treatment with an ACEi, a beta-blocker and an MRA*

I

B

*Patient should have elevated natriuretic peptides (plasma BNP ≥150 pg/mL or plasma NT-proBNP ≥600 pg/mL, or if HF hospitalization within the last 12 months, plasma BNP ≥100 pg/mL or plasma NT-proBNP ≥400 pg/mL) and able to tolerate enalapril 10 mg b.i.d. ACC, American College of Cardiology; AHA, American Heart Association; ACEI, angiotensin-convertingenzyme inhibitor; ARB, angiotensin II receptor blocker, ARNI, angiotensin receptor neprilysin inhibitor; CV, cardiovascular; ESC, European Society of Cardiology; HF, heart failure; HFSA, Heart Failure Society of America; HFrEF, HF with reduced ejection fraction; NYHA, New York Heart Association

Ponikowski et al. Eur Heart J. 21 May 2016. doi:10.1093/eurheartj/ehw128 Yancy et al. J Am Coll Cardiol. Published 21 May 2016. doi:10.1016/j.jacc.2016.05.011;

Therapeutic algorithm for a patient with symptomatic HF with reduced ejection fraction.

32

Yancy et al JACC 2016

LCZ696 verstärkt die vorteilhaften Effekte des NP Systems und hemmt gleichzeitig nachteilige Effekte des RAAS LCZ696 Sacubitril (Prodrug) Valsartan

↑ANP ANP BNP ↑BNP

CNP ↑CNP

NPR-A

NEP-Inhibitor

ANP ANP BNP BNP CNP CNP

NPR-B

(aktiver Metabolit [LBQ657])

NPR-C Neprilysin

GTP

GTP Endozytose

↑cGMP cGMP

AT1 Rezeptor

Rezeptorrecycling

SignaSignalkaskade kaskade

Inaktivierung der NP

Vasodilation

Vasokonstriktion

 Kardiale Fibrose/Hypertrophie

 Kardiale Fibrose/Hypertrophie

 Natriurese/Diurese

 Natrium-/Wasser-Retention

Levin et al. N Engl J Med 1998; Gardner et al. Hypertension 2007; Molkentin. J Clin Invest 2003; Nishikimi et al. Cardiovasc Res 2006 8; Guo et al. Cell Res 2001; von Lueder et al. Circ Heart Fail 2013;

Primärer Endpunkt: CV-bedingter Tod oder erste Hospitalisierung wg. Herzinsuffizienz

Kumulative Wahrscheinlichkeit

1,0

Enalapril Sacubitril/Valsartan (LCZ696)

0,6 Hazard Ratio = 0,80 [95% CI: 0,73 - 0,87) p 150ms Sacubitril/Valsartan: 1b Indikation, EF < 35% und Symptomatik (NYHA II !) trotz Standardtherapie nach Absetzten von ACEI/ARB

51

Case 1 NYHA II-Patient Parameter Gender Age, years

Value Female 55

Etiology

Ischemic cardiomyopathy

LVEF, %

35

Comorbidities NYHA class

DM, HTN II

Blood Pressure, mmHg

132/70

Heart Rate, bpm

66

E/E ´

15

Creatinine, mol/L

98

K, mEq/L

4.2

NT-proBNP, pg/mL Current Medication

LCZ 696?

1900 Ram 2x5mg, Meto 2x100mg, Torasemid 5mg, Eple 50mg

BNP=B-type natriuretic peptide; DM=Diabetes mellitus; HTN=hypertension; JVP=jugular venous pressure; LVEF=left ventricular ejection fraction; NYHA=New York Heart Association; NTproBNP=N-terminal pro-B-type natriuretic peptide

PARADIGM-HF: 70% NYHA II  70% of patients were NYHA class II – greater than in SOLVD-T (57%), possibly due to greater use of disease-modifying drugs/devices prior to enrolment in PARADIGM-HF

% of patients

NYHA class II 100 90 80 70 60 50 40 30 20 10 0

NYHA class III

100

80 73

70

69

57 49 30

50

30 24

24

20 0

SOLVD-T N=2569

CHARM-Added N=2548

HEAAL N=3834

RAFT N=1798

SHIFT EMPHASIS-HF PARADIGM-HF N=6505 N=2737 N=8442

McMurray et al. Eur J Heart Fail. 2014

Activation of the cardiac RAAS during CHF

Ang II Staining

Normal

20 Cardiac Ang II 15 Secretion 10 (pg/min/g) 79 patients 5 0 -5 -10

56

DCM

ICM

*

*

* DCM ICM Normal

I II III IV --------------- NHYA ------------Serneri et al., Circ Res 88: 961-968, 2001

Heart failure is not stable ! “stabile” Phase NYHA II

“instabile” Phase

Cardiac / renal function

AHF “stabile” Phase NYHA II

Hospitalisation due to WHF  Cardiac / Renalfunction

Time

1. Alla et al. Heart Fail Rev 2007;12:91–5; 2. Cleland et al. Eur Heart J 2003;24:442–636; 3. Gheorghiade et al. Am J Cardiol 2005;96:11G–17G

Beta-Blockers in patients with stable chronic Heart Failure: CIBIS-II-Study (1999)

CIBIS-II Investigators and Committes. Lancet 1999;353(9146):9-13.

Effect of treatments in „stable“ Heart Failure

Valsartan

Cohn et al. N Engl J Med 2001;345(23):1667-75.

Defi

Sport

63% NYHA II Stable HF

< Bardy et al. New Engl J Med 2005;352:225-37

O’Connor et al. JAMA 2009;301(14):1439-50

Case 1 NYHA II-Patient Parameter Gender Age, years

Value Female 55

Etiology

Ischemic cardiomyopathy

LVEF, %

35

Comorbidities NYHA class

DM, HTN II

Blood Pressure, mmHg

132/70

Heart Rate, bpm

66

E/E

`15

Creatinine, mol/L

98

K, mEq/L

4.2

NT-proBNP, pg/mL Current Medication

Would you consider prescribing LCZ 696 to this patient?

1900 Ram 2x5mg, Meto 2x100mg, Torasemid 5mg, Eple 50mg

BNP=B-type natriuretic peptide; DM=Diabetes mellitus; HTN=hypertension; JVP=jugular venous pressure; LVEF=left ventricular ejection fraction; NYHA=New York Heart Association; NTproBNP=N-terminal pro-B-type natriuretic peptide

NT-proBNP affects subsequent event rate NT-proBNP 1000

HR=0.41 (0.29,0.58) p 70bpm

Fortgeschrittene Therapie bei Beschwerden